German Biotech studies Autoimmune Diseases to develop new Therapeutics

19/07/2016 - 3 minutes

Patients suffering from a rare autoimmune disorder could actually be the key for a new promising type of antibodies. These are the findings of researchers from ImmunoQure and different European universities, now published in Cell.

immunoqure autoantibodies autoimmune inflammationMore than 40 years ago, the development of monoclonal antibodies really pushed the class of biologics forward.

Research on antibodies is still strong now, with new developments in cancer immunotherapies and new spins on these agents, from bispecific antibodies (like those developed by Genmab and Merus) to alpaca-derived mini-antibodies. Now, autoantibodies may be joining the list of exciting developments in the field.

Broadly, the term autoantibody describes any antibody that the human body produces against its own proteins – so the ‘bad guy‘ in serious autoimmune disorders.

However, researchers from ImmunoQure (a German Biotech) and several European universities (University of Tartu,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member